ReviewPhenomics (Cham, Switzerland)2026
Autophagy: A Novel Therapeutic Target for Osteoporosis.
Review in Phenomics (Cham, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autophagy is an evolutionarily conserved catabolic process in eukaryotes, which plays a vital role in the maintenance of cellular homeostasis. The occurrence of autophagy depends on lysosome, which is responsible for eliminating the dysfunctional cellular components, including misfolded proteins, impaired organelles and pathogens. Osteoporosis (OP) is a common bone metabolic disease, and it needs more therapeutic strategies that could restore the imbalance between bone formation and bone resorption, which is the main pathophysiological feature of OP. Interstingly, increasing evidence shows that autophagy is closely involved in bone metabolism, and its aberrant level leads to various skeletal system disorders, including OP. Autophagy regulates the survival, differentiation and function of bone marrow mesenchymal stromal cells (BMSCs), osteoblasts, osteocytes and osteoclasts, which are the major cell types in the bone microenvironment. Herein, we summarized the important advances of autophagy in bone metabolism, and the promising therapeutic strategies for OP by targeting autophagy. This review is aimed at providing novel insights for the prevention and treatment of OP via regulation of autophagy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.